US5166315A
(en)
*
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5235033A
(en)
*
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US5034506A
(en)
*
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5185444A
(en)
*
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
US5506337A
(en)
*
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
US5405938A
(en)
*
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5470974A
(en)
*
|
1985-03-15 |
1995-11-28 |
Neu-Gene Development Group |
Uncharged polynucleotide-binding polymers
|
US5521063A
(en)
*
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
DE3850273T2
(de)
*
|
1987-03-02 |
1994-09-29 |
Gen Probe Inc |
Polykationische Träger zur Reinigung, Trennung und Hybridisierung von Nukleinsäure.
|
US5599667A
(en)
*
|
1987-03-02 |
1997-02-04 |
Gen-Probe Incorporated |
Polycationic supports and nucleic acid purification separation and hybridization
|
IL86164A0
(en)
*
|
1987-04-28 |
1988-11-15 |
Tamir Biotechnology Ltd |
Improved dna probes
|
CA1308516C
(en)
*
|
1987-07-06 |
1992-10-06 |
J. William Lown |
Oligopeptide anticancer and antiviral agents
|
EP0333832B1
(de)
*
|
1987-09-22 |
1992-06-03 |
Temple University |
Künstliche analogen der dns-basenpaare
|
US6054266A
(en)
*
|
1987-12-21 |
2000-04-25 |
Applied Biosystems, Inc. |
Nucleic acid detection with separation
|
FR2627590A1
(fr)
*
|
1988-02-24 |
1989-08-25 |
Ire Celltarg Sa |
Sonde d'acides nucleiques comportant un nucleotide terminal modifie chimiquement en 5(prime) (oh) en vue de son marquage non radioactif et procedes de preparation
|
CA1337639C
(en)
*
|
1989-08-01 |
1995-11-28 |
Joseph Eugene Celebuski |
Dna probe assay using neutrally charged probe strands
|
EP0942000B1
(de)
|
1989-10-24 |
2004-06-23 |
Isis Pharmaceuticals, Inc. |
2'-Modifizierte Oligonukleotide
|
DE69033986T2
(de)
*
|
1989-12-20 |
2003-03-13 |
Antivirals Inc |
Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
|
US5378841A
(en)
*
|
1989-12-20 |
1995-01-03 |
Antivirals Inc. |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US6011020A
(en)
*
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US6465188B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US5783682A
(en)
*
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
BR9106702A
(pt)
*
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
US6121433A
(en)
*
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
US5610289A
(en)
*
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5618704A
(en)
*
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
CA2092002A1
(en)
*
|
1990-09-20 |
1992-03-21 |
Mark Matteucci |
Modified internucleoside linkages
|
US5175266A
(en)
*
|
1991-04-19 |
1992-12-29 |
Triplex Pharmaceutical Corporation |
Nucleosides and oligonucleosides with a phosphate-free internucleoside backbone and process for preparing the same
|
DK51092D0
(da)
*
|
1991-05-24 |
1992-04-15 |
Ole Buchardt |
Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
US6228982B1
(en)
*
|
1992-05-22 |
2001-05-08 |
Benget Norden |
Double-stranded peptide nucleic acids
|
US5766855A
(en)
*
|
1991-05-24 |
1998-06-16 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity and sequence specificity
|
US5719262A
(en)
*
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
US6441130B1
(en)
|
1991-05-24 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Linked peptide nucleic acids
|
US5539082A
(en)
*
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
US6451968B1
(en)
*
|
1991-05-24 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acids
|
US7223833B1
(en)
|
1991-05-24 |
2007-05-29 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid conjugates
|
US5714331A
(en)
*
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US6713602B1
(en)
|
1991-05-24 |
2004-03-30 |
Ole Buchardt |
Synthetic procedures for peptide nucleic acids
|
US5877160A
(en)
*
|
1991-05-31 |
1999-03-02 |
Genta Incorporated |
Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
|
EP0616612A4
(de)
|
1991-12-12 |
1995-01-11 |
Gilead Sciences Inc |
Nukleasestabile und bindungsfähige oligomere und verfahren zu ihrer verwendung.
|
US5792608A
(en)
*
|
1991-12-12 |
1998-08-11 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
US5359044A
(en)
*
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
MX9207334A
(es)
*
|
1991-12-18 |
1993-08-01 |
Glaxo Inc |
Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
|
ATE515510T1
(de)
*
|
1991-12-24 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
|
US5700922A
(en)
*
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US6277603B1
(en)
|
1991-12-24 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US6521601B1
(en)
*
|
1992-04-14 |
2003-02-18 |
Signal Pharmaceuticals, Inc. |
Method and composition for inhibition of viral replication
|
US5428148A
(en)
*
|
1992-04-24 |
1995-06-27 |
Beckman Instruments, Inc. |
N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
|
US6770738B1
(en)
*
|
1992-05-22 |
2004-08-03 |
Isis Pharmaceuticals, Inc. |
Higher order structure and binding of peptide nucleic acids
|
US5434257A
(en)
*
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
HUT72614A
(en)
*
|
1992-09-24 |
1996-05-28 |
Chiron Corp |
Synthesis of n-substituted oligomers
|
WO1994022891A1
(en)
*
|
1993-03-31 |
1994-10-13 |
Sterling Winthrop Inc. |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
US7825215B1
(en)
*
|
1993-04-26 |
2010-11-02 |
Peter E. Nielsen |
Substituted nucleic acid mimics
|
DE4331012A1
(de)
*
|
1993-09-13 |
1995-03-16 |
Bayer Ag |
Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
|
DE4331011A1
(de)
*
|
1993-09-13 |
1995-03-16 |
Bayer Ag |
Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
|
US7375198B2
(en)
|
1993-10-26 |
2008-05-20 |
Affymetrix, Inc. |
Modified nucleic acid probes
|
US6156501A
(en)
*
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
US6710164B1
(en)
|
1993-11-22 |
2004-03-23 |
Peter E. Nielsen |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US6133444A
(en)
|
1993-12-22 |
2000-10-17 |
Perseptive Biosystems, Inc. |
Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
|
US5705333A
(en)
*
|
1994-08-05 |
1998-01-06 |
The Regents Of The University Of California |
Peptide-based nucleic acid mimics(PENAMS)
|
DE4427980A1
(de)
*
|
1994-08-08 |
1996-02-15 |
Bayer Ag |
Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
|
US5552471A
(en)
*
|
1994-08-17 |
1996-09-03 |
The Perkin-Elmer Corporation |
Solid support reagents for the synthesis of 3'-Nitrogen containing polynucleotides
|
US6045995A
(en)
*
|
1994-08-24 |
2000-04-04 |
Isis Pharmaceuticals, Inc. |
Capillary electrophoretic detection of nucleic acids
|
PT804456E
(pt)
*
|
1994-10-06 |
2003-01-31 |
Peter Eigil Nielsen |
Conjugados de acidos nucleicos dos peptidos
|
UA48150C2
(uk)
*
|
1994-11-02 |
2002-08-15 |
Ай-Сі-Ен Фармасьютикалз |
Похідні амінокислот або аміноспиртів, олігонуклеотид
|
EP0817787A4
(de)
|
1995-03-27 |
2000-09-13 |
Isis Pharmaceuticals Inc |
Makrozyklische stickstoffverbindungen
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
JPH11507352A
(ja)
|
1995-06-07 |
1999-06-29 |
ジンタ・インコーポレイテッド |
新規カルバメート基本カチオン性脂質
|
JP2001518054A
(ja)
*
|
1995-06-07 |
2001-10-09 |
パーセプティブ バイオシステムズ,インコーポレーテッド |
Pna−dnaキメラと、このキメラ合成用のpnaシントン
|
JPH11506605A
(ja)
*
|
1995-06-07 |
1999-06-15 |
アボツト・ラボラトリーズ |
増幅反応におけるバックグラウンドを減少させるためにプローブをマスキングする方法
|
ATE362546T1
(de)
|
1995-10-12 |
2007-06-15 |
Lansdorp Peter M |
Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül
|
JP3346976B2
(ja)
*
|
1996-03-18 |
2002-11-18 |
理化学研究所 |
完全長cDNAライブラリーの作成方法
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20050032068A1
(en)
*
|
2002-11-05 |
2005-02-10 |
Prakash Thazha P. |
Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
ATE311402T1
(de)
*
|
1996-07-24 |
2005-12-15 |
Buchardt Dorte |
Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
|
US5919638A
(en)
*
|
1996-10-08 |
1999-07-06 |
Abbott Laboratories |
Reagents and methods useful for detecting prostate tumors
|
US5908845A
(en)
*
|
1996-10-30 |
1999-06-01 |
Segev; David |
Polyether nucleic acids
|
US20050153373A1
(en)
*
|
1996-10-31 |
2005-07-14 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US20050202499A1
(en)
*
|
1996-10-31 |
2005-09-15 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US20030165971A1
(en)
*
|
1996-10-31 |
2003-09-04 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6060246A
(en)
*
|
1996-11-15 |
2000-05-09 |
Avi Biopharma, Inc. |
Reagent and method for isolation and detection of selected nucleic acid sequences
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6046004A
(en)
*
|
1997-02-27 |
2000-04-04 |
Lorne Park Research, Inc. |
Solution hybridization of nucleic acids with antisense probes having modified backbones
|
US6251591B1
(en)
|
1997-02-27 |
2001-06-26 |
Lorne Park Research, Inc. |
Quantitative method for detecting nucleotide concentration
|
US20020137904A1
(en)
*
|
1998-03-27 |
2002-09-26 |
Patricia A. Billing-Medel |
Reagents and methods useful for detecting diseases of the gastrointestinal tract
|
US20050208567A1
(en)
*
|
1997-04-25 |
2005-09-22 |
Billing-Medel Patricia A |
Reagents and methods useful for detecting diseases of the prostate
|
US5962665A
(en)
|
1997-06-16 |
1999-10-05 |
Abbott Laboratories |
Nucleic acid primers and probes for detecting HIV-1 and HIV-2
|
JP4313861B2
(ja)
|
1997-08-01 |
2009-08-12 |
キヤノン株式会社 |
プローブアレイの製造方法
|
WO1999011820A1
(en)
*
|
1997-09-02 |
1999-03-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the identification and quantitation of deletion sequence oligonucleotides in synthetic oligonucleotide preparations
|
US6300318B1
(en)
|
1997-09-16 |
2001-10-09 |
Peter E. Nielsen |
Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
|
US6723560B2
(en)
|
1998-10-08 |
2004-04-20 |
Mayo Foundation For Medical Education And Research |
Using polyamide nucleic acid oligomers to engender a biological response
|
US6989270B1
(en)
|
1997-10-17 |
2006-01-24 |
Mayo Foundation For Medical Education And Research |
Using polyamide nucleic acid oligomers to engender a biological response
|
US6472209B1
(en)
|
1997-10-17 |
2002-10-29 |
Mayo Foundation For Medical Education And Research |
Using polyamide nucleic acid oligomers to engender a biological response
|
US6326479B1
(en)
|
1998-01-27 |
2001-12-04 |
Boston Probes, Inc. |
Synthetic polymers and methods, kits or compositions for modulating the solubility of same
|
US6255050B1
(en)
|
1998-05-22 |
2001-07-03 |
Lorne Park Research, Inc. |
Dynamic hybridization system
|
EP1095054B1
(de)
|
1998-07-09 |
2006-10-25 |
Biocept, Inc. |
Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US6175004B1
(en)
*
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
US6720139B1
(en)
|
1999-01-27 |
2004-04-13 |
Elitra Pharmaceuticals, Inc. |
Genes identified as required for proliferation in Escherichia coli
|
JP2002535015A
(ja)
*
|
1999-01-29 |
2002-10-22 |
エイブイアイ バイオファーマ, インコーポレイテッド |
標的rnaを検出するための非侵襲性方法
|
DK1175497T3
(da)
|
1999-04-14 |
2010-05-31 |
Novartis Vaccines & Diagnostic |
Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
|
US6348583B1
(en)
*
|
1999-08-30 |
2002-02-19 |
Bio-Rad Laboratories, Inc. |
Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
|
AU2041901A
(en)
|
1999-11-09 |
2001-06-06 |
Elitra Pharmaceuticals, Inc. |
Genes essential for microbial proliferation and antisense thereto
|
KR20030003221A
(ko)
*
|
1999-12-23 |
2003-01-09 |
엘리트라 파마슈티컬즈, 인코포레이티드 |
대장균 증식에 필요한 유전자
|
AU3087801A
(en)
*
|
2000-02-04 |
2001-08-14 |
Molecular Dynamics Inc |
Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
|
US7211381B1
(en)
|
2000-04-04 |
2007-05-01 |
Abbott Laboratories |
β2 andrenergic polymorphism detection
|
US6593092B2
(en)
|
2000-04-04 |
2003-07-15 |
Abbott Laboratories |
Beta 2 adrenergic polymorphism detection
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
EP3020804A1
(de)
|
2000-07-06 |
2016-05-18 |
Sarepta Therapeutics, Inc. |
Umwandlung der wachstumsfaktor-beta (tgf-beta) blockierungsmittelbehandelten stammzellenzusammensetzung und verfahren
|
US6867349B2
(en)
|
2000-07-31 |
2005-03-15 |
Regents Of The University Of Minnesota |
Inhibition of gene expression using polynucleotide analogues
|
US8071740B2
(en)
|
2000-11-17 |
2011-12-06 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
US6838452B2
(en)
|
2000-11-24 |
2005-01-04 |
Vascular Biogenics Ltd. |
Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
|
CA2436665C
(en)
|
2001-01-29 |
2012-01-10 |
Bio-Rad Laboratories, Inc. |
Nucleic acid derivatives
|
WO2002078638A2
(en)
*
|
2001-03-30 |
2002-10-10 |
University Of Massachusetts |
Morpholino imaging and therapy
|
EP1470245A4
(de)
*
|
2001-04-24 |
2005-08-31 |
Pharmacia & Upjohn Co Llc |
Einzelnukleotid-polymorphismen-diagnostikum für schizophrenie
|
EP1925672A1
(de)
|
2001-06-22 |
2008-05-28 |
Syngeta Participations AG |
Auf abiotischen Stress ansprechende Polynukleotide und Polypeptide
|
US20030198621A1
(en)
|
2001-07-05 |
2003-10-23 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
EP1423536A2
(de)
*
|
2001-08-28 |
2004-06-02 |
PHARMACIA & UPJOHN COMPANY |
Diagnostik auf der basis von einzelnukleotid polymorphismen auf schizophrenie
|
US20040115699A1
(en)
*
|
2001-08-28 |
2004-06-17 |
Kaytes Paul S. |
Single nucleotide polymorphisms diagnostic for schizophrenia
|
US6852491B2
(en)
|
2001-09-04 |
2005-02-08 |
Abbott Laboratories |
Amplification and detection reagents for HIV-1
|
US20030224353A1
(en)
*
|
2001-10-16 |
2003-12-04 |
Stein David A. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
EP2277887A3
(de)
|
2001-10-19 |
2011-02-16 |
Vascular Biogenics Ltd. |
Polynukleotidkonstrukte, pharmazeutische Zusammensetzungen und Verfahren zur gezielten Abwärtsregulation der Angiogenese und Therapie gegen Krebs
|
US20040029129A1
(en)
*
|
2001-10-25 |
2004-02-12 |
Liangsu Wang |
Identification of essential genes in microorganisms
|
EP1440072A4
(de)
|
2001-10-30 |
2005-02-02 |
Conforma Therapeutic Corp |
Purinanaloga mit hsp90-inhibierender wirkung
|
AU2002360349A1
(en)
*
|
2001-11-09 |
2003-05-26 |
Pharmacia And Upjohn Company |
Single nucleotide polymorphisms in gh-1
|
US20030170694A1
(en)
*
|
2001-12-21 |
2003-09-11 |
Daniel Wall |
Stabilized nucleic acids in gene and drug discovery and methods of use
|
US20050037962A1
(en)
*
|
2002-01-18 |
2005-02-17 |
Ekker Stephen C. |
Syndecans and angiogenesis
|
US20030220249A1
(en)
*
|
2002-02-07 |
2003-11-27 |
Hackett Perry B. |
Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation, and methods of use thereof
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US7026120B2
(en)
|
2002-04-15 |
2006-04-11 |
Abbott Laboratories |
Probes for detecting tumor cells
|
US7015317B2
(en)
*
|
2002-05-02 |
2006-03-21 |
Abbott Laboratories |
Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US7807802B2
(en)
|
2002-11-12 |
2010-10-05 |
Abbott Lab |
Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
WO2004056868A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Endocube Sas |
Nf-hev compositions and methods of use
|
EP1605978B1
(de)
|
2003-03-07 |
2010-09-01 |
Alnylam Pharmaceuticals Inc. |
Therapeutische zusammensetzungen
|
EP2669377A3
(de)
|
2003-04-17 |
2015-10-14 |
Alnylam Pharmaceuticals Inc. |
Modifizierte iRNA-Wirkstoffe
|
NZ542097A
(en)
|
2003-04-29 |
2008-12-24 |
Pfizer Ltd |
5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
US20050026189A1
(en)
*
|
2003-05-29 |
2005-02-03 |
Liangsu Wang |
Microbial operons
|
WO2005013905A2
(en)
*
|
2003-08-07 |
2005-02-17 |
Avi Biopharma, Inc. |
SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
|
US20050153935A1
(en)
*
|
2003-09-12 |
2005-07-14 |
Iversen Patrick L. |
Compound and method for treating androgen-independent prostate cancer
|
BRPI0414533A
(pt)
|
2003-09-18 |
2006-11-07 |
Conforma Therapeutics Corp |
composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
|
US7125945B2
(en)
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
DK2666481T3
(en)
|
2003-12-26 |
2019-02-25 |
Masatoshi Hagiwara |
A method for regulating the phosphorylation of SR protein and antiviral agents comprising an SR protein activity regulator as the active ingredient
|
WO2005067646A2
(en)
|
2004-01-07 |
2005-07-28 |
Hitachi Chemical Research Center, Inc. |
Primers and probes for the detection of hiv
|
WO2005072527A2
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005097799A1
(en)
|
2004-04-07 |
2005-10-20 |
Pfizer Limited |
Pyrazolo`4,3-d! pyrimidines
|
AU2005252662B2
(en)
*
|
2004-06-03 |
2011-08-18 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP4272748A3
(de)
|
2004-06-28 |
2024-03-27 |
The University Of Western Australia |
Antisense-oligonukleotide zur induzierung von exon-skipping und verfahren zur verwendung davon
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
DK1766012T3
(da)
|
2004-07-02 |
2011-09-19 |
Avi Biopharma Inc |
Antisense-antibakteriel fremgangsmåde og forbindelse
|
US7729761B2
(en)
|
2004-07-14 |
2010-06-01 |
Cardiac Pacemakers, Inc. |
Method and apparatus for controlled gene or protein delivery
|
EP1791567B1
(de)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemisch modifizierte oligonucleotide
|
JPWO2006025154A1
(ja)
*
|
2004-08-30 |
2008-05-08 |
国立大学法人岐阜大学 |
修飾オリゴヌクレオチド
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US8129352B2
(en)
*
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
US8357664B2
(en)
|
2004-10-26 |
2013-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
US7524829B2
(en)
*
|
2004-11-01 |
2009-04-28 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
CN101072585A
(zh)
|
2004-11-01 |
2007-11-14 |
诺华疫苗和诊断公司 |
产生免疫应答的组合方法
|
US20090118132A1
(en)
*
|
2004-11-04 |
2009-05-07 |
Roche Molecular Systems, Inc. |
Classification of Acute Myeloid Leukemia
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
MX2007011903A
(es)
|
2005-03-30 |
2007-12-05 |
Conforma Therapeutics Corp |
Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
|
US20060240032A1
(en)
*
|
2005-03-31 |
2006-10-26 |
Hinrichs David J |
Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
|
WO2006121764A2
(en)
*
|
2005-05-06 |
2006-11-16 |
Applera Corporation |
Multiple capillary device and method for synthesis and dispensing
|
US7790694B2
(en)
*
|
2005-07-13 |
2010-09-07 |
Avi Biopharma Inc. |
Antisense antibacterial method and compound
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
AU2006267051B2
(en)
|
2005-07-13 |
2013-03-07 |
Sarepta Therapeutics, Inc. |
Antisense antibacterial method and compound
|
US7868161B2
(en)
*
|
2005-07-29 |
2011-01-11 |
North Carolina State University |
Photocrosslinking probes and uses of the same
|
AU2006281569A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of CK19 expression
|
EP1937278B1
(de)
*
|
2005-09-08 |
2012-07-25 |
AVI BioPharma, Inc. |
Antivirale antisense-verbindung und verfahren zur behandlung von picornavirus-infektion
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
US8906609B1
(en)
|
2005-09-26 |
2014-12-09 |
Arrowhead Center, Inc. |
Label-free biomolecule sensor based on surface charge modulated ionic conductance
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
ATE467688T1
(de)
*
|
2006-03-07 |
2010-05-15 |
Avi Biopharma Inc |
Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
|
RU2394915C2
(ru)
*
|
2006-03-24 |
2010-07-20 |
Александр Борисович Четверин |
Бесконтактные способы обнаружения молекулярных колоний, наборы реагентов и устройство для их осуществления
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
JP2010505741A
(ja)
*
|
2006-05-10 |
2010-02-25 |
エイブイアイ バイオファーマ, インコーポレイテッド |
カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ
|
US20070265215A1
(en)
*
|
2006-05-11 |
2007-11-15 |
Iversen Patrick L |
Antisense restenosis composition and method
|
US7592009B2
(en)
*
|
2006-10-10 |
2009-09-22 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Polypeptide ligands for targeting cartilage and methods of use thereof
|
ES2798758T3
(es)
*
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
ES2694726T3
(es)
|
2007-06-29 |
2018-12-26 |
Sarepta Therapeutics, Inc. |
Conjugados peptídicos específicos de tejido y métodos
|
AU2008333811B2
(en)
|
2007-12-04 |
2014-05-01 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
AU2008345033B2
(en)
*
|
2007-12-28 |
2014-04-03 |
Sarepta Therapeutics, Inc. |
Immunomodulatory agents and methods of use
|
EP2274425A2
(de)
|
2008-04-11 |
2011-01-19 |
Alnylam Pharmaceuticals Inc. |
Stellenspezifische zuführung von nukleinsäuren durch kombinieren zielgerichteter liganden mit endosomolytischen komponenten
|
AU2009298802A1
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
JP5864257B2
(ja)
|
2008-10-24 |
2016-02-17 |
サレプタ セラピューティクス, インコーポレイテッド |
Dmdのための複数のエキソンスキッピング組成物
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
CA2746508A1
(en)
*
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
JP5548852B2
(ja)
*
|
2009-05-29 |
2014-07-16 |
国立大学法人東京農工大学 |
疎水性基結合ヌクレオシド、疎水性基結合ヌクレオシド溶液、及び疎水性基結合オリゴヌクレオチド合成方法
|
WO2010141511A2
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
DK2440183T3
(en)
|
2009-06-10 |
2018-10-01 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
EP2462230B1
(de)
*
|
2009-08-03 |
2015-07-15 |
Recombinetics, Inc. |
Verfahren und zusammensetzungen für gezielte genmodifikation
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
CN105838714B
(zh)
|
2009-11-12 |
2020-07-17 |
西澳大利亚大学 |
反义分子和治疗疾病的方法
|
EP3199634A1
(de)
|
2009-11-13 |
2017-08-02 |
Sarepta Therapeutics, Inc. |
Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
US8592364B2
(en)
*
|
2010-02-11 |
2013-11-26 |
Ecole Polytechnique Federale de Lausanne (“EPFL”) |
CCR7 ligand delivery and co-delivery in immunotherapy
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
EP2545173A2
(de)
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense-modulation von nukleären hormonrezeptoren
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP2558069A1
(de)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridinzusammensetzungen und ihre verwendung
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
AU2011248625B2
(en)
|
2010-04-26 |
2017-01-05 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ, インコーポレイテッド |
イソロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
US9068177B2
(en)
|
2010-04-29 |
2015-06-30 |
Atyr Pharma, Inc |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
CA2797393C
(en)
|
2010-04-29 |
2020-03-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
CA2797978C
(en)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
CN103096925A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
CN102985103A
(zh)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
|
US9050373B2
(en)
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
JP6396656B2
(ja)
|
2010-05-14 |
2018-09-26 |
エータイアー ファーマ, インコーポレイテッド |
フェニルアラニルβtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
JP6027965B2
(ja)
|
2010-05-17 |
2016-11-16 |
エータイアー ファーマ, インコーポレイテッド |
ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
AU2011257980B2
(en)
|
2010-05-28 |
2016-06-30 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
CA2804416C
(en)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
WO2012031243A2
(en)
|
2010-09-03 |
2012-03-08 |
Avi Biopharma, Inc. |
dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
|
CA2817090A1
(en)
|
2010-11-12 |
2012-05-18 |
Sarepta Therapeutics, Inc. |
Antisense antibacterial compounds and methods
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
JP2014507143A
(ja)
|
2011-02-08 |
2014-03-27 |
ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム |
アンチセンスオリゴヌクレオチド
|
US9528124B2
(en)
|
2013-08-27 |
2016-12-27 |
Recombinetics, Inc. |
Efficient non-meiotic allele introgression
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
KR102339196B1
(ko)
|
2011-05-05 |
2021-12-15 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
펩타이드 올리고뉴클레오타이드 접합체
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2729168A2
(de)
|
2011-07-06 |
2014-05-14 |
Novartis AG |
Immunogene zusammensetzungen und ihre verwendungen
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
AU2012284259A1
(en)
|
2011-07-15 |
2014-03-06 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
US9801948B2
(en)
|
2011-09-21 |
2017-10-31 |
Yale University |
Antimicrobial compositions and methods of use thereof
|
US9701623B2
(en)
|
2011-09-27 |
2017-07-11 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
KR102271212B1
(ko)
|
2011-11-18 |
2021-07-01 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
|
AU2012345638C1
(en)
|
2011-11-30 |
2018-10-18 |
Sarepta Therapeutics, Inc. |
Induced exon inclusion in spinal muscle atrophy
|
WO2013082548A1
(en)
|
2011-11-30 |
2013-06-06 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
WO2013082529A1
(en)
|
2011-12-02 |
2013-06-06 |
Yale University |
Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
|
US10465042B2
(en)
|
2011-12-02 |
2019-11-05 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
US9895451B2
(en)
|
2011-12-02 |
2018-02-20 |
Yale University |
Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
|
HUE038369T2
(hu)
|
2011-12-08 |
2018-10-29 |
Sarepta Therapeutics Inc |
Humán LMNA-t célzó oligonukleotid-analógok
|
NZ700399A
(en)
|
2012-03-20 |
2016-07-29 |
Sarepta Therapeutics Inc |
Boronic acid conjugates of oligonucleotide analogues
|
EP3563872A1
(de)
|
2012-04-05 |
2019-11-06 |
Massachusetts Institute Of Technology |
Immunstimulationszusammensetzungen und verfahren zur verwendung davon
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
KR102240217B1
(ko)
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
KR20200143739A
(ko)
|
2012-12-20 |
2020-12-24 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
|
WO2014113540A1
(en)
|
2013-01-16 |
2014-07-24 |
Iowa State University Research Foundation, Inc. |
A deep intronic target for splicing correction on spinal muscular atrophy gene
|
KR102384693B1
(ko)
|
2013-03-12 |
2022-04-07 |
유니버시티 오브 유타 리서치 파운데이션 |
세포사멸 유도용 조성물 및 방법
|
DK2970964T3
(en)
|
2013-03-14 |
2019-04-01 |
Sarepta Therapeutics Inc |
EXON SKIPPING COMPOSITIONS FOR TREATMENT OF MUSCLE DYROPHY
|
EA035882B1
(ru)
|
2013-03-14 |
2020-08-27 |
Сарепта Терапьютикс, Инк. |
Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
|
BR112015022998A2
(pt)
|
2013-03-15 |
2017-11-14 |
Sarepta Therapeutics Inc |
composições melhoradas para o tratamento de distrofia muscular
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
US20150197534A1
(en)
|
2013-09-05 |
2015-07-16 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
EP3791862A1
(de)
|
2013-09-11 |
2021-03-17 |
Eagle Biologics, Inc. |
Flüssige proteinformulierungen mit viskositätssenkenden mitteln
|
US10059947B2
(en)
|
2013-09-11 |
2018-08-28 |
Synthena Ag |
Nucleic acids and methods for the treatment of Pompe disease
|
US9708360B2
(en)
|
2013-09-30 |
2017-07-18 |
Geron Corporation |
Phosphorodiamidate backbone linkage for oligonucleotides
|
AU2014337790B2
(en)
|
2013-10-25 |
2019-09-26 |
Livestock Improvement Corporation Limited |
Genetic markers and uses therefor
|
EP3143141B1
(de)
|
2014-05-16 |
2019-10-02 |
Oregon State University |
Antibakterielle antisense-verbindungen und verfahren
|
AU2015264449B2
(en)
|
2014-05-19 |
2022-05-05 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
US20170182189A1
(en)
|
2014-05-23 |
2017-06-29 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
RU2697502C2
(ru)
|
2014-07-24 |
2019-08-14 |
Эбботт Молекьюлар Инк. |
Композиции и способы обнаружения и анализа микобактерии туберкулеза (mycobacterium tuberculosis)
|
SG10201902499VA
(en)
|
2014-09-03 |
2019-04-29 |
Genesegues Inc |
Therapeutic nanoparticles and related compositions, methods and systems
|
KR102617137B1
(ko)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
US10682422B2
(en)
|
2014-11-18 |
2020-06-16 |
Yale University |
Formulations for targeted release of agents under low pH conditions and methods of use thereof
|
WO2016081621A1
(en)
|
2014-11-18 |
2016-05-26 |
Yale University |
Formulations for targeted release of agents under low ph conditions and methods of use thereof
|
CA2972653A1
(en)
|
2014-12-31 |
2016-07-07 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
CN107106694B
(zh)
|
2015-01-13 |
2020-09-22 |
西格亚有限公司 |
在水中用于制备透明质酸钠盐的丁酸酯类的方法
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
US20180126014A1
(en)
|
2015-04-15 |
2018-05-10 |
Yale University |
Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
|
WO2016187425A1
(en)
|
2015-05-19 |
2016-11-24 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
EP3851531A1
(de)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Antisense-induzierte exonexklusion in typ-vii-kollagen
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
CN108184327A
(zh)
|
2015-07-14 |
2018-06-19 |
雅培分子公司 |
用于鉴定耐药性结核的组合物和方法
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス, インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
US10370667B2
(en)
|
2015-11-18 |
2019-08-06 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
|
EP3377629B1
(de)
|
2015-11-18 |
2023-07-05 |
Rosalind Franklin University of Medicine and Science |
Antisense-verbindungen gegen leucinereiche repeat-kinase 2 (lrrk2) zur behandlung der parkinsonschen krankheit
|
CA3006748A1
(en)
|
2015-12-15 |
2017-06-22 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
EP3394261A4
(de)
|
2015-12-23 |
2019-11-27 |
Oregon State University |
Antibakterielle antisense-verbindungen und verfahren
|
AU2016379402B2
(en)
|
2015-12-23 |
2023-01-12 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
US11136597B2
(en)
|
2016-02-16 |
2021-10-05 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
CN109072240A
(zh)
|
2016-02-26 |
2018-12-21 |
耶鲁大学 |
使用piRNA诊断和治疗癌症的组合物和方法
|
US20210189062A1
(en)
|
2016-03-01 |
2021-06-24 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45471A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
KR102329187B1
(ko)
|
2016-04-29 |
2021-11-22 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
인간 lmna를 표적화하는 올리고뉴클레오타이드 유사체
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
MA45158A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Composition pharmaceutique comprenant de l'éteplirsen
|
MA45362A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
CN109563114B
(zh)
|
2016-05-24 |
2022-08-12 |
萨勒普塔医疗公司 |
用于制备寡聚物的方法
|
US11472824B2
(en)
|
2016-05-24 |
2022-10-18 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
WO2017205879A2
(en)
|
2016-05-24 |
2017-11-30 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
WO2017205880A1
(en)
|
2016-05-24 |
2017-11-30 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
CN109311920B
(zh)
|
2016-05-24 |
2021-11-09 |
萨勒普塔医疗公司 |
制备磷酸二酰胺吗啉代寡聚物的方法
|
US10925973B2
(en)
|
2016-06-15 |
2021-02-23 |
University Of Utah Research Foundation |
Compositions and methods for using albumin-based nanomedicines
|
JP2019525742A
(ja)
|
2016-06-30 |
2019-09-12 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマー
|
JP6920411B2
(ja)
*
|
2016-07-25 |
2021-08-18 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
コリンキナーゼ阻害剤としてのプリン及び3−デアザプリンアナログ
|
CN116804031A
(zh)
|
2016-09-20 |
2023-09-26 |
科罗拉多州立大学董事会法人团体 |
使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
|
WO2018112470A1
(en)
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
BR112019012647A2
(pt)
|
2016-12-19 |
2019-11-19 |
Sarepta Therapeutics Inc |
conjugados de oligômero de salto de éxon para distrofia muscular
|
WO2018118627A1
(en)
|
2016-12-19 |
2018-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
AU2017382773A1
(en)
|
2016-12-19 |
2019-08-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
JP2020517638A
(ja)
|
2017-04-20 |
2020-06-18 |
エータイアー ファーマ, インコーポレイテッド |
肺の炎症を治療するための組成物および方法
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
NL2019390B1
(en)
|
2017-08-04 |
2019-02-21 |
Univ Leiden |
Screening Method
|
WO2019032827A1
(en)
|
2017-08-09 |
2019-02-14 |
Massachusetts Institute Of Technology |
PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
|
US11833156B2
(en)
|
2017-09-22 |
2023-12-05 |
Jubilant Epipad LLC |
Heterocyclic compounds as pad inhibitors
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
EP3687519A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
WO2019071028A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
FI3697785T3
(fi)
|
2017-10-18 |
2023-04-03 |
Jubilant Epipad LLC |
Imidatsopyridiiniyhdisteitä pad:n estäjinä
|
EP3707135A1
(de)
*
|
2017-11-06 |
2020-09-16 |
Jubilant Prodel LLC |
Pyrimidinderivate als inhibitoren der pd1/pd-l1-aktivierung
|
GB201718804D0
(en)
*
|
2017-11-14 |
2017-12-27 |
Nuclera Nucleics Ltd |
Novel use
|
US10953036B2
(en)
|
2017-11-20 |
2021-03-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of modulating HIF-2A to improve muscle generation and repair
|
JP7368369B2
(ja)
|
2017-11-24 |
2023-10-24 |
ジュビラント・エピスクライブ・エルエルシー |
Prmt5阻害剤としてのヘテロ環式化合物
|
MX2020005860A
(es)
|
2017-12-06 |
2020-09-09 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
|
EP3724335A1
(de)
|
2017-12-11 |
2020-10-21 |
Rosalind Franklin University of Medicine and Science |
Antisense-verbindungen gegen leucinreiche repeat-kinase 2 (lrrk2) zur behandlung der parkinsonschen krankheit
|
WO2019139997A1
(en)
|
2018-01-09 |
2019-07-18 |
Trucode Gene Repair, Inc. |
Polymer-based nanoparticles, related formulation methods, and apparatus
|
JP7279063B6
(ja)
|
2018-03-13 |
2024-02-15 |
ジュビラント プローデル エルエルシー |
Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
EP3806868A4
(de)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
WO2020028133A1
(en)
|
2018-07-30 |
2020-02-06 |
Trucode Gene Repair, Inc. |
Lipid nanoparticle formulations comprising nucleic acid mimics
|
US11939593B2
(en)
|
2018-08-01 |
2024-03-26 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
WO2020051507A1
(en)
|
2018-09-06 |
2020-03-12 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
KR20210104759A
(ko)
|
2018-12-13 |
2021-08-25 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근 이영양증을 위한 엑손 스키핑 올리고머 접합체
|
IL297818A
(en)
|
2018-12-21 |
2023-01-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
EP3918069A1
(de)
|
2019-01-31 |
2021-12-08 |
Bar Ilan University |
Durch aberrant-induziertes spleissen erzeugte neoantigene und deren verwendung zur verstärkung einer immuntherapie
|
WO2020198268A1
(en)
|
2019-03-28 |
2020-10-01 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
US11814464B2
(en)
|
2019-04-29 |
2023-11-14 |
Yale University |
Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
|
US11578090B2
(en)
|
2019-06-06 |
2023-02-14 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
WO2020257489A1
(en)
|
2019-06-19 |
2020-12-24 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
WO2021025899A1
(en)
|
2019-08-02 |
2021-02-11 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer pharmaceutical compositions
|
CA3149421A1
(en)
|
2019-08-30 |
2021-03-04 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
WO2021154705A1
(en)
|
2020-01-27 |
2021-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021163281A1
(en)
|
2020-02-12 |
2021-08-19 |
Accutar Biotechnology Inc. |
Antisense oligonucleotides and their use for treating pendred syndrome
|
JP2023537798A
(ja)
|
2020-03-19 |
2023-09-06 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
US20230233693A1
(en)
|
2020-06-19 |
2023-07-27 |
Yale University |
Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
|
EP4204002A1
(de)
|
2020-08-31 |
2023-07-05 |
Yale University |
Zusammensetzungen und verfahren zur abgabe von nukleinsäuren an zellen
|
WO2022140535A1
(en)
|
2020-12-23 |
2022-06-30 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
EP4330395A1
(de)
|
2021-04-30 |
2024-03-06 |
Sarepta Therapeutics, Inc. |
Behandlungsverfahren für muskeldystrophie
|
GB202107553D0
(en)
|
2021-05-27 |
2021-07-14 |
Univ Oxford Innovation Ltd |
Method
|
GB202111250D0
(en)
|
2021-08-04 |
2021-09-15 |
Univ Oxford Innovation Ltd |
Method
|
WO2023034515A2
(en)
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
CA3233242A1
(en)
|
2021-09-30 |
2023-04-06 |
Sarepta Therapeutics, Inc. |
Antisense oligonucleotides having one or more abasic units
|
WO2023070086A1
(en)
|
2021-10-22 |
2023-04-27 |
Sarepta Therapeutics, Inc. |
Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
|
WO2023159189A1
(en)
|
2022-02-18 |
2023-08-24 |
Yale University |
Branched poly(amine-co-ester) polymers for more efficient nucleic expression
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
WO2023178230A1
(en)
|
2022-03-17 |
2023-09-21 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
WO2024015924A2
(en)
|
2022-07-15 |
2024-01-18 |
Entrada Therapeutics, Inc. |
Hybrid oligonucleotides
|
WO2024064237A2
(en)
|
2022-09-21 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Dmd antisense oligonucleotide-mediated exon skipping efficiency
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|